Heptaminol

Structural formula
	Structural formula without stereochemistry
General
Non-proprietary name	Heptaminol
other names	( RS ) -6-amino-2-methylheptan-2-ol ( IUPAC ) ; (±) -6-Amino-2-methylheptan-2-ol; Heptaminolum ( Latin ) ;
Molecular formula	C 8 H 19 NO
Brief description	colorless liquid (base, racemate)
External identifiers / databases
ECHA InfoCard	100.006.144
PubChem	3590
Wikidata	Q417921
Drug information
ATC code	C01 DX08
Drug class	Sympathomimetics
properties
Molar mass	145.24 g · mol -1 (base) ; 181.71 g · mol -1 (hydrochloride) ;
Melting point	<25 ° C (base, racemate)
boiling point	99-105 ° C ( base, racemate , 931 Pa); 110 ° C ( base, racemate , 1.73 kPa); 178–180 ° C (hydrochloride, racemate) ;
safety instructions
	Please note the exemption from the labeling requirement for drugs, medical devices, cosmetics, food and animal feed
H and P phrases	H: 314-315-319-335
	P: ?
Toxicological data	1250 mg kg −1 ( LD 50 , mouse , ip , base, racemate) ; 900 mg kg −1 ( LD 50 , mouse , ip , hydrochloride, racemate) ;
	As far as possible and customary, SI units are used. Unless otherwise noted, the data given apply to standard conditions .

Heptaminol is a 1: 1 mixture ( racemate ) of two enantiomeric chemical compounds from the group of amino alcohols , which is used as a drug in the group of sympathomimetics in the treatment of cardiovascular diseases . Heptaminol was developed by Bilhuber and patented in 1948. The racemate of the drug is used as a more water-soluble hydrochloride and as an ester acefylline-heptaminol with acefylline (1,2,3,6-tetrahydro-1,3-dimethyl-2,6-dioxopurine-7-acetic acid).

Clinical information

Heptaminol is used for hypotension , "old age heart", as well as for accompanying therapy with digitalism medication . Usually, a dose of 150 mg three times a day ( orally ) or 200 mg twice a day as a sustained- release formulation.

Pharmacological properties

Heptaminol has an indirect sympathomimetic effect by inhibiting the reuptake of noradrenaline in the synaptic gap . Heptaminol has a plasma half-life from 2.5 to 2.7 hours and is unchanged in the urine excreted .

Other Information

Heptaminol is used for doping purposes. It is listed on the World Anti-Doping Agency (WADA) list as a stimulant that is prohibited during athletic competitions.

Trade names

Heptylon
Generics

Individual evidence

↑ ^a ^b ^c ^d ^e ^f ^g Entry on heptaminol. In: Römpp Online . Georg Thieme Verlag, accessed on July 12, 2011.
↑ ^a ^b Entry on heptaminol in the ChemIDplus database of the United States National Library of Medicine (NLM) .
↑ Template: CL Inventory / not harmonized There is not yet a harmonized classification for this substance . A labeling of heptaminol in the Classification and Labeling Inventory of the European Chemicals Agency (ECHA), which was accessed on March 27, 2020, is reproduced from a self-classification by the distributor .
^ H. Grobecker: On the mode of action of heptaminol . In: Naunyn-Schmiedeberg's Archives of Pharmacology . 266, No. 4-5, 1970, pp. 339-340. doi : 10.1007 / BF00997979 .
^ F. Kees: Bioavailability studies of heptaminol in healthy volunteers . In: drug research . 37, No. 10, 1987, pp. 1182-1185.
↑ The World Anti-Doping Code: The 2009 Prohibited List, International Standard , p. 7 ( Memento of July 19, 2014 in the Internet Archive ) (PDF; 177 kB).

[römpp-1] ↑ ^a ^b ^c ^d ^e ^f ^g Entry on heptaminol. In: Römpp Online . Georg Thieme Verlag, accessed on July 12, 2011.

[ChemIDplus-2] Entry on heptaminol in the ChemIDplus database of the United States National Library of Medicine (NLM) .

[3] Template: CL Inventory / not harmonized There is not yet a harmonized classification for this substance . A labeling of heptaminol in the Classification and Labeling Inventory of the European Chemicals Agency (ECHA), which was accessed on March 27, 2020, is reproduced from a self-classification by the distributor .

[4] H. Grobecker: On the mode of action of heptaminol . In: Naunyn-Schmiedeberg's Archives of Pharmacology . 266, No. 4-5, 1970, pp. 339-340. doi : 10.1007 / BF00997979 .

[5] F. Kees: Bioavailability studies of heptaminol in healthy volunteers . In: drug research . 37, No. 10, 1987, pp. 1182-1185.

[6] The World Anti-Doping Code: The 2009 Prohibited List, International Standard , p. 7 ( Memento of July 19, 2014 in the Internet Archive ) (PDF; 177 kB).